In the dynamic world of pharmaceutical development, the availability of high-quality chemical intermediates is paramount. Among these, (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol, identified by CAS number 1006376-60-8, stands out as a critical building block. This chiral alcohol derivative, with its specific difluorophenyl structure, plays an indispensable role, most notably in the synthesis of Ticagrelor. Ticagrelor is a groundbreaking medication, a reversible oral P2Y12 receptor antagonist, revolutionizing the treatment of acute coronary syndromes by offering superior inhibition compared to older drugs.

The significance of (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol extends beyond its application in a single drug. As a versatile organic synthesis building block, it allows chemists to construct complex molecular architectures. This capability is essential for drug discovery, enabling researchers to explore new chemical entities and potential therapeutic targets. The precision offered by this compound in chemical reactions ensures higher yields and purities, which are critical factors in pharmaceutical manufacturing. Companies looking to buy (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol are seeking to secure a reliable supply of a compound that underpins the production of vital medicines.

The demand for this specific intermediate highlights the growing importance of fluorinated organic compounds in modern chemistry. The difluorophenyl moiety contributes unique electronic and steric properties that are often leveraged to enhance drug efficacy, metabolic stability, and bioavailability. For pharmaceutical manufacturers, sourcing this intermediate often involves partnering with specialized chemical suppliers who can guarantee consistent quality and adhere to stringent regulatory standards. The ability to procure this pharmaceutical intermediate efficiently directly impacts the speed and cost-effectiveness of drug production.

Understanding the synthesis of (1S)-2-chloro-1-(3,4-difluorophenyl)-1-ethanol is also key for optimization. While traditional chemical synthesis methods are employed, ongoing research often explores more efficient and environmentally friendly routes, potentially involving biocatalysis. The consistent quality and availability of this intermediate are vital for maintaining the supply chain for Ticagrelor and other potential pharmaceuticals that may utilize this unique molecular structure. For those in the chemical industry, securing a dependable pharmaceutical intermediate supplier for compounds like this is a strategic imperative for sustained growth and innovation.